ACAD Q2 2020 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$110M+32.3% YoY

Gross Profit

$105M95.0% margin

Operating Income

-$44M-40.0% margin

Net Income

-$42M-38.3% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+22.2%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$40M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$760M

Total Liabilities

$97M

Stockholders' Equity

$663M

Cash & Equivalents

$310M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$110M	$83M	+32.3%
Gross Profit	$105M	$78M	+33.8%
Operating Income	-$44M	-$57M	+22.9%
Net Income	-$42M	-$55M	+23.3%